Join
Live feed
·
PRReleasevia Quantisnow
Alumis Inc. logo
ACELYRIN INC. logo

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

ByQuantisnow·Wall Street's wire, on your screen.
ALMS· Alumis Inc.SLRN· ACELYRIN INC.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALMS (Alumis Inc.), SLRN (ACELYRIN INC.) and more on Quantisnow.

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases | Quantisnow